Drug Profile


Alternative Names: BCT-197; BCT197A2201

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Developer Mereo BioPharma; Novartis
  • Class Anti-inflammatories; Antibronchitics; Benzamides; Cyclopropanes; Pyrazoles; Small molecules
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease
  • Discontinued Acute kidney injury

Most Recent Events

  • 26 May 2017 Mereo BioPharma completes enrolment in the AETHER trial for Chronic obstructive pulmonary disease in USA, Bulgaria, Czech Republic, Germany, Hungary, Italy, Latvia, Poland, Romania, Russia and United Kingdom (PO) (NCT02700919)
  • 13 Dec 2016 Mereo BioPharma has patent protection for Acumapimod in United Kingdom and USA
  • 01 Oct 2016 Mereo BioPharma completes a drug-interaction phase I trial in Healthy volunteers in the United Kingdom (NCT02926326)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top